Corcept Therapeutics reported 6M in Interest Expense on Debt for its fiscal quarter ending in June of 2024.


Interest Expense On Debt Change Date
Acadia Pharmaceuticals 0 4.12M Sep/2024
Alaunos Therapeutics USD 0 0 Dec/2023
ANI Pharmaceuticals USD 5.44M 46K Jun/2025
Ardelyx USD 6.58M 2.61M Jun/2025
Aurora Cannabis CAD 1.78M 491K Jun/2025
BioMarin Pharmaceutical USD 2.68M 184K Jun/2025
Bristol-Myers Squibb USD 485M 9M Jun/2025
Canopy Growth CAD 9.74M 7.03M Jun/2025
Corcept Therapeutics 6M 6M Jun/2024
Eli Lilly USD 249M 5.3M Jun/2025
J&J USD 128M 9M Mar/2025
Knight Therapeutics CAD 1.91M 369K Sep/2024
Merck USD 305M 8M Jun/2025
Novartis USD 289M 19M Jun/2025
Novartis USD 289M 14M Jun/2025
Pacira USD 3.82M 110K Jun/2025
Pfizer USD 654M 0 Jun/2025
Supernus Pharmaceuticals USD 0 0 Dec/2024
TG Therapeutics USD 6.72M 4.12M Jun/2025